Amicus Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Amicus Therapeutics

27/02/2023 15:42

* Amicus Therapeutics Inc  FOLD.OQ   FOLD.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 1. 
    * The Philadelphia Pennsylvania-based  company is expected
to
report  a 5.0% increase in revenue to $86.289 million from
$82.15 million a year ago, according to the mean estimate from
11 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Amicus Therapeutics
Inc
is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $16​, above​ its last closing price
of $12.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.19       -0.19      -0.12     Beat    35.6
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    3.2
 Mar. 31 2022  -0.26       -0.25      -0.30     Missed  -17.6​
 Dec. 31 2021  -0.15       -0.16      -0.29     Missed  -85.9
 ​​Sep.        -0.17       -0.17      -0.19     Missed  -13
 30 2021                                                
 Jun. 30 2021  -0.22       -0.21      -0.19     Beat    10.1​
 Mar. 31 2021  -0.24       -0.23      -0.25     Missed  -6.4
 Dec. 31 2020  -0.24       -0.22      -0.27     Missed  -24.4
 This summary was machine generated February 27 at 15:42 GMT. 
All figures in US dollars  unless otherwise stated